ULI's ceftriaxone sodium injection passes consistency evaluation

The United Laboratories International Holdings Limited (HKEX: 3933) announced that its Ceftriaxone Sodium for Injection (specifications: 1.0g; 2.0g) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the company, has passed the consistency evaluation for generic drugs. The approval, granted by China National Medical Products Administration, covers the consistency evaluation of quality and efficacy for generic drugs. Ceftriaxone sodium for injection is applicable to the treatment of infections caused by sensitive pathogens. The company believes this approval will further solidify its position in the anti-infective field. Ceftriaxone sodium for injection has been listed in the National Essential Drug List (2018 edition) and Category A in the National Medical Insurance Drug List (2024 edition).